Overview

A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Status:
Completed
Trial end date:
2018-08-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of Ibrutinib in Japanese participants with treatment-naive chronic lymphocytic leukemia ( CLL) or small lymphocytic lymphoma (SLL).
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Pharmaceutical K.K.